20-Aug-2026
Aurinia settles Lupkynis patent litigation with Teva
Seeking Alpha News (Wed, 19-Aug 5:12 PM ET)
TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer
TipRanks (Wed, 19-Aug 11:16 AM ET)
Teva gets FDA priority review for Tourette syndrome therapy
Seeking Alpha News (Wed, 19-Aug 8:54 AM ET)
Globe Newswire (Wed, 19-Aug 8:30 AM ET)
Piper Sandler Reaffirms Their Buy Rating on Teva Pharmaceutical (TEVA)
TipRanks (Tue, 18-Aug 7:16 AM ET)
Globe Newswire (Tue, 11-Aug 8:00 AM ET)
Market Chameleon (Wed, 29-Jul 7:14 AM ET)
Teva’s Key Brands Drive Portfolio Transformation as Innovation Pipeline Expands
Market Chameleon (Wed, 29-Jul 3:36 AM ET)
Globe Newswire (Wed, 29-Jul 7:00 AM ET)
Globe Newswire (Thu, 9-Jul 8:30 AM ET)
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Teva Pharmaceutical Industries Limited American Depositary Shares trades on the NYSE stock market under the symbol TEVA.
As of August 20, 2026, TEVA stock price declined to $36.81 with 3,894,626 million shares trading.
TEVA has a beta of 0.93, meaning it tends to be less sensitive to market movements. TEVA has a correlation of 0.08 to the broad based SPY ETF.
TEVA has a market cap of $42.87 billion. This is considered a Large Cap stock.
Last quarter Teva Pharmaceutical Industries Limited American Depositary Shares reported $4 billion in Revenue and $.02 earnings per share. This beat revenue expectation by $74 million and missed earnings estimates by -$.39.
In the last 3 years, TEVA traded as high as $37.83 and as low as $8.06.
The top ETF exchange traded funds that TEVA belongs to (by Net Assets): IEFA, EFA, EIS, EFG, WCMI.
TEVA has outperformed the market in the last year with a price return of +109.6% while the SPY ETF gained +20.4%. TEVA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +8.0% and +6.0%, respectively, while the SPY returned +4.2% and -0.9%, respectively.
TEVA support price is $36.69 and resistance is $38.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TEVA shares will trade within this expected range on the day.